LogicBio Therapeutics

LogicBio Therapeutics

  • Founded: 2014
  • Location: Lexington, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Genetic diseases
  • Drug types: GEN, RAR, PED
  • Lead product: GeneRide platform
  • Product link: https://www.logicbio.com/overview
  • Funding: $48M stock Oct 2020; $80.5M IPO Oct 2018; $45M B Jun 2017; $4M Jan 2016



job board

Short description:

Gene Therapy

Drug notes:

Also sAAVy platform

Long description:

LogicBio Therapeutics is developing genetic medicines to fight against rare pediatric diseases. LogicBio is pioneering safer, site-specific genome editing technology to provide durable therapies using their GeneRide proprietary platform. LogicBio has currently designed GeneRide to identify liver-targeted therapies - the platform uses a synthetic viral vector to deliver the corrective transgene to a patient's cell into the highly-expressed albumin locus. By using a 2A peptide, both the corrective transgene and albumin are produced as separate protein products and modify albumin with a small tag to monitor GeneRide activity. LogicBio’s initial product candidates will address diseases by targeting the liver, but the company is looking to expand to other tissues.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com